
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7219550/publications.pdf Version: 2024-02-01



DETED C. SMITH

#	Article	IF	CITATIONS
1	Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet, The, 2022, 399, 924-944.	6.3	752
2	Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials. Clinical Infectious Diseases, 2014, 58, 470-480.	2.9	749
3	Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet, The, 1998, 351, 1540-1543.	6.3	213
4	MMR vaccination and pervasive developmental disorders: a case-control study. Lancet, The, 2004, 364, 963-969.	6.3	203
5	Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. Journal of Infectious Diseases, 2020, 221, 1752-1756.	1.9	186
6	First generation leishmaniasis vaccines: A review of field efficacy trials. Vaccine, 2008, 26, 6759-6767.	1.7	153
7	Variability of Infectious Aerosols Produced during Coughing by Patients with Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 450-457.	2.5	132
8	A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine, 1999, 17, 466-472.	1.7	131
9	Validation of the diagnosis of autism in general practitioner records. BMC Public Health, 2004, 4, 5.	1.2	123
10	Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis—A meta-analysis. Vaccine, 2009, 27, 4747-4753.	1.7	121
11	Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. Lancet Infectious Diseases, The, 2019, 19, e31-e38.	4.6	120
12	Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial. PLoS Neglected Tropical Diseases, 2010, 4, e709.	1.3	114
13	Bovine spongiform encephalopathy (BSE) and its epidemiology. British Medical Bulletin, 2003, 66, 185-198.	2.7	110
14	Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine, 2021, 39, 4013-4024.	1.7	110
15	Predictability of the UK Variant Creutzfeldt-Jakob Disease Epidemic. Science, 2001, 294, 1729-1731.	6.0	109
16	Risk factors for variant Creutzfeldt-Jakob disease: A case-control study. Annals of Neurology, 2006, 59, 111-120.	2.8	100
17	The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field. Clinical Infectious Diseases, 2016, 62, 69-74.	2.9	84
18	Combined Analysis of Mortality in Three United Kingdom Nuclear Industry Workforces, 1946-1988. Radiation Research, 1994, 138, 224.	0.7	79

#	Article	IF	CITATIONS
19	Obstacles to conducting epidemiological research in the UK general population. BMJ: British Medical Journal, 2004, 329, 277-279.	2.4	79
20	Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine, 2017, 35, 3295-3302.	1.7	77
21	Fetal death and congenital malformation in babies born to nuclear industry employees: report from the nuclear industry family study. Lancet, The, 2000, 356, 1293-1299.	6.3	75
22	Evaluation of diagnostic tests for infectious diseases: general principles. Nature Reviews Microbiology, 2010, 8, S16-S28.	13.6	74
23	WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016. Vaccine, 2019, 37, 7307-7314.	1.7	74
24	Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial. PLoS Neglected Tropical Diseases, 2014, 8, e2613.	1.3	71
25	Tuberculosis in developing countries and methods for its control. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 739-744.	0.7	70
26	Rate and Amplification of Drug Resistance among Previouslyâ€Treated Patients with Tuberculosis in Kampala, Uganda. Clinical Infectious Diseases, 2008, 47, 1126-1134.	2.9	63
27	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. New England Journal of Medicine, 2020, 382, 1366-1369.	13.9	63
28	Attempted Suicide as Language: An Empirical Study. British Journal of Psychiatry, 1970, 116, 465-473.	1.7	57
29	Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. Expert Review of Vaccines, 2009, 8, 705-716.	2.0	56
30	The inheritance of translocations in man: data from families ascertained through a balanced heterozygote. Annals of Human Genetics, 1970, 34, 119-136.	0.3	55
31	Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. Vaccine, 2020, 38, 2435-2448.	1.7	54
32	Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy. Vaccine, 2019, 37, 7372-7380.	1.7	53
33	Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. Vaccine, 2018, 36, 3411-3417.	1.7	52
34	Risk factors for sporadic Creutzfeldt–Jakob disease. Annals of Neurology, 2008, 63, 347-354.	2.8	51
35	Effectiveness of the Standard WHO Recommended Retreatment Regimen (Category II) for Tuberculosis in Kampala, Uganda: A Prospective Cohort Study. PLoS Medicine, 2011, 8, e1000427.	3.9	49
36	Human respiratory syncytial virus and influenza seasonality patterns—Early findings from the WHO global respiratory syncytial virus surveillance. Influenza and Other Respiratory Viruses, 2020, 14, 638-646.	1.5	49

#	Article	IF	CITATIONS
37	Structure, function and five basic needs of the global health research system. Journal of Global Health, 2016, 6, 010508.	1.2	48
38	Cancer in children of nuclear industry employees: report on children aged under 25Âyears from nuclear industry family study. BMJ: British Medical Journal, 1999, 318, 1443-1450.	2.4	46
39	Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Vaccine, 2017, 35, 5535-5542.	1.7	46
40	Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. Vaccine, 2019, 37, 7394-7395.	1.7	46
41	Placebo use in vaccine trials: Recommendations of a WHO expert panel. Vaccine, 2014, 32, 4708-4712.	1.7	45
42	Observational study to estimate the changes in the effectiveness of bacillus Calmette–Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technology Assessment, 2017, 21, 1-54.	1.3	45
43	Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7–9th Sep 2015. Vaccine, 2016, 34, 2865-2869.	1.7	43
44	Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group. Vaccine, 2021, 39, 633-640.	1.7	42
45	The duration of protection of school-aged BCG vaccination in England: a population-based case–control study. International Journal of Epidemiology, 2018, 47, 193-201.	0.9	41
46	Clinical characteristics, predictors, and performance of case definition—Interim results from the WHO global respiratory syncytial virus surveillance pilot. Influenza and Other Respiratory Viruses, 2020, 14, 647-657.	1.5	40
47	Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda. Annals of Clinical Microbiology and Antimicrobials, 2007, 6, 1.	1.7	39
48	WHO consultation on ETEC and Shigella burden of disease, Geneva, 6–7th April 2017: Meeting report. Vaccine, 2019, 37, 7381-7390.	1.7	39
49	Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation. Vaccine, 2013, 31, 2603-2609.	1.7	37
50	The Incubation Period of Kuru. Epidemiology, 2002, 13, 402-408.	1.2	36
51	Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malaria Journal, 2015, 14, 160.	0.8	36
52	The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. Vaccine, 2019, 37, 3190-3198.	1.7	35
53	A case-control study of autism and mumps-measles-rubella vaccination using the general practice research database: design and methodology. BMC Public Health, 2001, 1, 2.	1.2	32
54	Antiretroviral treatment in resource-poor settings: public health research priorities. Tropical Medicine and International Health, 2005, 10, 295-299.	1.0	32

#	Article	IF	CITATIONS
55	Rate of first recorded diagnosis of autism and other pervasive developmental disorders in United Kingdom general practice, 1988 to 2001. BMC Medicine, 2004, 2, 39.	2.3	31
56	Case-control vaccine effectiveness studies: Data collection, analysis and reporting results. Vaccine, 2017, 35, 3303-3308.	1.7	31
57	Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance—opportunities and challenges. Influenza and Other Respiratory Viruses, 2020, 14, 622-629.	1.5	31
58	Concepts of herd protection and immunity. Procedia in Vaccinology, 2010, 2, 134-139.	0.4	30
59	The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study. Emerging Themes in Epidemiology, 2015, 12, 1.	1.2	30
60	Choices in vaccine trial design in epidemics of emerging infections. PLoS Medicine, 2018, 15, e1002632.	3.9	29
61	Effects of misclassification of causes of death on the power of a trial to assess the efficacy of a pneumococcal conjugate vaccine in The Gambia. International Journal of Epidemiology, 2003, 32, 430-436.	0.9	27
62	Social and Environmental Influences on Child Mortality in Brazil: Logistic Regression Analysis of Data from Census Files. Journal of Biosocial Science, 1986, 18, 87-102.	0.5	26
63	A Cluster-Randomised Trial to Compare Home-Based with Health Facility-Based Antiretroviral Treatment in Uganda: Study Design and Baseline Findings. Open AIDS Journal, 2007, 1, 21-27.	0.1	26
64	A study of measles virus and canine distemper virus antibodies, and of childhood infections in multiple sclerosis patients and controls. Journal of the Neurological Sciences, 1982, 56, 1-10.	0.3	25
65	Multiple sclerosis and dog ownership. Journal of the Neurological Sciences, 1982, 55, 359-367.	0.3	25
66	Epidemiological studies of the â€~nonâ€specific effects' of vaccines: I – data collection in observational studies. Tropical Medicine and International Health, 2009, 14, 969-976.	1.0	25
67	Treatment Outcomes of New Tuberculosis Patients Hospitalized in Kampala, Uganda: A Prospective Cohort Study. PLoS ONE, 2014, 9, e90614.	1.1	24
68	Vaccine-attributable severe dengue in the Philippines. Lancet, The, 2019, 394, 2151-2152.	6.3	23
69	Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines. Wellcome Open Research, 2019, 4, 165.	0.9	23
70	The epidemics of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: current status and future prospects. Bulletin of the World Health Organization, 2003, 81, 123-30.	1.5	22
71	Preparation for a pneumococcal vaccine trial in The Gambia: individual or community randomisation?. Vaccine, 1999, 18, 633-640.	1.7	20
72	Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden. Influenza and Other Respiratory Viruses, 2020, 14, 615-621.	1.5	20

#	Article	IF	CITATIONS
73	Integrating health services for HIV infection, diabetes and hypertension in sub-Saharan Africa: a cohort study. BMJ Open, 2021, 11, e053412.	0.8	20
74	WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use. Vaccine, 2022, 40, 3506-3510.	1.7	20
75	Sex ratio of nuclear industry employees'children. Lancet, The, 2001, 357, 1589-1591.	6.3	19
76	Evaluation of diagnostic tests for infectious diseases: general principles. Nature Reviews Microbiology, 2007, 5, S21-S31.	13.6	18
77	Ethics of HIV trials. Lancet, The, 1997, 350, 1546.	6.3	17
78	Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014–2015 outbreak. Clinical Trials, 2016, 13, 13-21.	0.7	17
79	The predictability of the epidemic of variant Creutzfeldt-Jakob disease by back-calculation methods. Statistical Methods in Medical Research, 2003, 12, 203-220.	0.7	16
80	Sensitivity and negative predictive value for a rapid dengue test. Lancet Infectious Diseases, The, 2019, 19, 465-466.	4.6	16
81	Evaluation of diagnostic tests for infectious diseases: general principles. Nature Reviews Microbiology, 2008, 6, S16-S28.	13.6	14
82	Sharing clinical trial data. Lancet, The, 2016, 387, 2287.	6.3	13
83	Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda. BMC Infectious Diseases, 2009, 9, 139.	1.3	12
84	Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection. Vaccine, 2009, 27, 5633-5643.	1.7	12
85	Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths. Vaccine, 2011, 29, 3686-3694.	1.7	12
86	Global diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection. Vaccine, 2021, 39, 4391-4398.	1.7	12
87	Evaluation of adverse effects of vaccines: the case-control approach. Vaccine, 2002, 20, 2611-2617.	1.7	11
88	Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review. Malaria Journal, 2009, 8, 23.	0.8	10
89	Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials, 2011, 12, 66.	0.7	10
90	Ethical issues in intervention studies on the prevention and management of diabetes and hypertension in sub-Saharan Africa. BMJ Global Health, 2020, 5, e002193.	2.0	10

PETER G SMITH

#	Article	IF	CITATIONS
91	Drug misuse, tobacco smoking, alcohol and other social determinants of tuberculosis in UK-born adults in England: a community-based case-control study. Scientific Reports, 2020, 10, 5639.	1.6	9
92	Exercise electrocardiogram tests in manual workers with and without antibodies to Trypanosoma cruzi: a population-based study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 787-791.	0.7	8
93	Making sense of health estimates. Lancet, The, 2015, 385, 1377-1379.	6.3	8
94	The nuclear industry family study: linkage of occupational exposures to reproduction and child health. BMJ: British Medical Journal, 1999, 318, 1453-1454.	2.4	6
95	Response to Cioffi. Journal of Infectious Diseases, 2020, 222, 169-170.	1.9	6
96	Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop. Vaccine, 2022, 40, 3484-3489.	1.7	6
97	Editorial: Scaleâ€up of antiretroviral therapy in sub‣aharan Africa – priorities for public health research. Tropical Medicine and International Health, 2007, 12, 1009-1010.	1.0	5
98	A vaccine against malaria: a substantial step forward. Lancet, The, 2009, 373, 1411-1412.	6.3	5
99	Novel vaccine safety issues and areas that would benefit from further research. BMJ Global Health, 2021, 6, e003814.	2.0	4
100	The 1957 MRC report on leukaemia and aplastic anaemia in patients irradiated for ankylosing spondylitis. Journal of Radiological Protection, 2007, 27, B3-B14.	0.6	2
101	Response to Dawson et al. Journal of Infectious Diseases, 2020, 222, 516-517.	1.9	2
102	Daan Mulder Memorial Symposium - Introduction. Tropical Medicine and International Health, 2000, 5, A1-A2.	1.0	1
103	Reply to Hasford and to Spinola et al. Journal of Infectious Diseases, 2020, 222, 1574-1575.	1.9	0
104	Integrating HIV, diabetes and hypertension services in Africa: study protocol for a cluster randomised trial in Tanzania and Uganda. BMJ Open, 2021, 11, e047979.	0.8	0